All Stories

  1. Host-microbe interactions mediate doramectin-promoted metabolic reprogramming of CD8+ T-cells and amplify antitumor immunity
  2. Lactic Fermentation of Broccoli (Brassica oleracea var. italica) to Enhance the Antioxidant and Antiproliferative Activities
  3. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health
  4. Strategies for the Identification and Assessment of Bacterial Strains with Specific Probiotic Traits
  5. Effects of a Modern Kefir on Conditions Associated with Moderate Severe Spastic Quadriparesis Cerebral Palsy
  6. Functional Foods, Nutraceuticals and Probiotics: A Focus on Human Health
  7. Looking inside Mexican Traditional Food as Sources of Synbiotics for Developing Novel Functional Products
  8. Genome Sequence and Assessment of Safety and Potential Probiotic Traits of Lactobacillus johnsonii CNCM I-4884
  9. Probiotics against Viral Infections: Current Clinical Trials and Future Perspectives
  10. Probiotics and Trained Immunity
  11. Age and Giardia intestinalis Infection Impact Canine Gut Microbiota
  12. Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium
  13. Antioxidant and Anti-Inflammatory Properties of Probiotic Candidate Strains Isolated during Fermentation of Agave (Agave angustifolia Haw)
  14. Anti-microbiota vaccines modulate the tick microbiome in a taxon-specific manner
  15. Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression
  16. Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease
  17. Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response
  18. Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3
  19. Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35
  20. Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis
  21. Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response
  22. Retraction Note to: Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer
  23. The Administration Matrix Modifies the Beneficial Properties of a Probiotic Mix of Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus acidophilus LA-5
  24. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains
  25. Gut Microbiota Abrogates Anti-α-Gal IgA Response in Lungs and Protects against Experimental Aspergillus Infection in Poultry
  26. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes
  27. Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3
  28. Targeting Melanoma Hypoxia with the Food-Grade Lactic Acid Bacterium Lactococcus Lactis
  29. Probiotics as Anti-Giardia Defenders: Overview on Putative Control Mechanisms
  30. Probiotic Properties of Lactobacillus Strains Isolated from Table Olive Biofilms
  31. Abdominoplasty in Hemodialysis Patients Before Transplant
  32. Oral delivery of pancreatitis‐associated protein by Lactococcus lactis displays protective effects in dinitro‐benzenesulfonic‐acid‐induced colitis model and is able to modulate the composition of the microbiota
  33. From Probiotics to Psychobiotics: Live Beneficial Bacteria Which Act on the Brain-Gut Axis
  34. Phosphatidylglycerols are novel lipids dysregulated in obesity
  35. The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response
  36. Anti-tumoral Effects of Recombinant Lactococcus lactis Strain Secreting IL-17A Cytokine
  37. Elucidating the Immune-Related Mechanisms by Which Probiotic Strain Lactobacillus casei BL23 Displays Anti-tumoral Properties
  38. A New Bifidobacteria Expression SysTem (BEST) to Produce and Deliver Interleukin-10 in Bifidobacterium bifidum
  39. M cell–targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing L. lactis
  40. Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP
  41. Live bacterial biotherapeutics in the clinic
  42. Latency and amplitude changes in cognitive event related potentials due to hemodialysis
  43. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance
  44. A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain
  45. Searching for the Bacterial Effector: The Example of the Multi-Skilled Commensal Bacterium Faecalibacterium prausnitzii
  46. Bile Salt Hydrolase Activities: A Novel Target to Screen Anti-Giardia Lactobacilli?
  47. Bile-Salt-Hydrolases from the Probiotic Strain Lactobacillus johnsonii La1 Mediate Anti-giardial Activity in Vitro and in Vivo
  48. Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?
  49. Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer
  50. New Insights into the Diversity of the Genus Faecalibacterium
  51. Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?
  52. Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic
  53. Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis
  54. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria
  55. Contribution of sortase SrtA2 to Lactobacillus casei BL23 inhibition of Staphylococcus aureus internalization into bovine mammary epithelial cells
  56. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis
  57. Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model
  58. The use of Mexican xaxtle as leavening agent in Italian straight dough bread making to produce pulque bread
  59. Erratum to: Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model
  60. Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
  61. Metagenomic analysis of the human microbiome
  62. Brief cognitive behavioural intervention for depression and anxiety symptoms improves quality of life in chronic haemodialysis patients
  63. A large scale in vitro screening of Streptococcus thermophilus strains revealed strains with a high anti-inflammatory potential
  64. Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice
  65. A new lactobacilliin vivoexpression system for the production and delivery of heterologous proteins at mucosal surfaces
  66. Gnotobiotic Rodents: An In Vivo Model for the Study of Microbe–Microbe Interactions
  67. Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector
  68. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models
  69. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer
  70. The secreted l-arabinose isomerase displays anti-hyperglycemic effects in mice
  71. Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model
  72. Drying process strongly affects probiotics viability and functionalities
  73. Identification of novel anti-inflammatory probiotic strains isolated from pulque
  74. Engineering Lactic Acid Bacteria and Bifidobacteria for Mucosal Delivery of Health Molecules
  75. Identification of an anti-inflammatory protein fromFaecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease
  76. Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of Faecalibacterium prausnitzii
  77. Intranasal administration with recombinant Lactococcus lactis expressing heme oxygenase-1 reduces hyperoxia-induced lung inflammation in rat pups
  78. Effect of iron on the probiotic properties of the vaginal isolate Lactobacillus jensenii CECT 4306
  79. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model
  80. Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
  81. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci
  82. Construction d’un vecteur d’expression chez Lactococcus lactis basée sur la production d’une protéine ancrée de Papillomavirus humain 16 E2/E7
  83. Lactobacillus rhamnosusCNCM I-3690 and the commensal bacteriumFaecalibacterium prausnitziiA2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice
  84. Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models
  85. The Indigenous Microbiota and its Potential to Exhibit Probiotic Properties
  86. Protective Effects of Lactococci Strains Delivering Either IL-10 Protein or cDNA in a TNBS-induced Chronic Colitis Model
  87. Selection of Anti-Inflammatory Lactic Acid Bacteria From A Pool of Yoghurt Starter Cultures
  88. Gut ecosystem: how microbes help us
  89. The Dual Role of MAPK Pathway in the Regulation of Intestinal Barrier
  90. Tu1778 Faecalibacterium prausnitzii Prevents Irritable Bowel Syndrome-Like Symptoms in Both Murine Low Grade Chronic Inflammation and Acute Stress Models
  91. Tu1746 Faecalibacterium prausnitzii Provides Host Beneficial Metabolic Profile During Inflammation
  92. 83 Identification of an Anti-Inflammatory Protein From Faecalibacterium prausnitzii, a Deficient Commensal Bacteria Implicated in Crohn's Disease
  93. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation
  94. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders
  95. The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models
  96. The role of metagenomics in understanding the human microbiome in health and disease
  97. Ecology and metabolism of the beneficial intestinal commensal bacteriumFaecalibacterium prausnitzii
  98. Genetically Engineered Immunomodulatory Streptococcus thermophilus Strains Producing Antioxidant Enzymes Exhibit Enhanced Anti-Inflammatory Activities
  99. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces
  100. Nuclease A (Gbs0661), an extracellular nuclease ofStreptococcus agalactiae, attacks the neutrophil extracellular traps and is needed for full virulence
  101. Engineering lactococci and lactobacilli for human health
  102. Faecalibacterium prausnitzii and human intestinal health
  103. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update
  104. Tu1988 Impact of the Commensal Bacterium Faecalibacterium prausnitzii in a Non Active Inflammation Murine Model
  105. Implications of the human microbiome in inflammatory bowel diseases
  106. Erratum to: Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface
  107. Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease
  108. Anti-Inflammatory Properties of Genetically Modified Lactic Acid Bacteria
  109. Contributors
  110. Identification of One Novel Candidate Probiotic Lactobacillus plantarum Strain Active against Influenza Virus Infection in Mice by a Large-Scale Screening
  111. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface
  112. Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis
  113. Functional Analysis of the Lactobacillus casei BL23 Sortases
  114. Inactivation of theybdDGene in Lactococcus lactis Increases the Amounts of Exported Proteins
  115. Importance of Commensal and Probiotic Bacteria in Human Health
  116. Mo1855 Oral Treatment With Elafin-Recombinant Probiotics Improves Visceral Pain and Hypersensitivity in a Model of Irritable Bowel Syndrome (IBS)
  117. Mo2015 Food-Grade Lactic Acid Bacteria Expressing Elastase Inhibitors Protect From Intestinal Inflammation in Acute and Chronic Models of Colitis in Mice
  118. Sa2060 Gnotobiotic Mice, a Promising Tool to Better Understand the Anti-Inflammatory Effects of Faecalibacterium prausnitziï?
  119. Sa2061 Protective and Curative Effect of Faecalibacterium prausnitzii in a Chronic DNBS-Induced Murine Colitis
  120. Tu1842 Elastolytic Balance in IBD: the Elastase Inhibitor Elafin Prevents Loss of Barrier Function and Cytokines Release by Human Intestinal Epithelial Cells in IBD Conditions
  121. Anti-inflammatory properties of dairy lactobacilli
  122. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection
  123. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment
  124. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice
  125. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines
  126. Variations of N-acetylation level of peptidoglycan do not influence persistence of Lactococcus lactis in the gastrointestinal tract
  127. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice
  128. Perspectives for the development of human papillomavirus vaccines and immunotherapy
  129. Utilisation des bactéries lactiques comme vecteurs vaccinaux
  130. Protective Effects of a Heme Oxygenase-1-Secreting Lactococcus lactis on Mucosal Injury Induced by Hemorrhagic Shock in Rats
  131. Lactococcus lactisas a live vector for mucosal delivery of therapeutic proteins
  132. Development of Mucosal Vaccines Based on Lactic Acid Bacteria
  133. Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium
  134. Allergy Therapy by Intranasal Administration with Recombinant Lactococcus lactis Producing Bovine β-Lactoglobulin
  135. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
  136. Production of biologically active CXC chemokines by Lactococcus lactis: Evaluation of its potential as a novel mucosal vaccine adjuvant
  137. Anti-inflammatory Properties of Lactic Acid Bacteria: Current Knowledge,Applications and Prospects
  138. Intragastric administration with recombinant Lactococcus lactis producing heme oxygenase-1 prevents lipopolysaccharide-induced endotoxemia in rats
  139. Production of biological active murine IFN-γ by recombinant Lactococcus lactis
  140. Consumption of Camembert cheese stimulates commensal enterococci in healthy human intestinal microbiota
  141. Current Prophylactic and Therapeutic Uses of a Recombinant Lactococcus lactis Strain Secreting Biologically Active Interleukin-12
  142. Lactococcus lactis, an Efficient Cell Factory for Recombinant Protein Production and Secretion
  143. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria
  144. Effects of Intranasal Administration of a Leptin-Secreting Lactococcus lactis Recombinant on Food Intake, Body Weight, and Immune Response of Mice
  145. Intranasal Coadministration of Live Lactococci Producing Interleukin-12 and a Major Cow's Milk Allergen Inhibits Allergic Reaction in Mice
  146. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice
  147. Antimicrobial Activity of Divercin RV41 Produced and Secreted by Lactococcus lactis
  148. Construction and characterization of a Lactococcus lactis strain deficient in intracellular ClpP and extracellular HtrA proteases
  149. Des bactéries pour prévenir et traiter le cancer du col de l’utérus induit par le papillomavirus humain de type 16
  150. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice
  151. A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors
  152. Improvement of bovine ß-lactoglobulin production and secretion by Lactococcus lactis
  153. Cell-surface display of E7 antigen from human papillomavirus type-16 inLactococcus lactisand inLactobacillus plantarumusing a new cell-wall anchor from lactobacilli
  154. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci
  155. Article
  156. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein
  157. Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon inLactococcus lactis
  158. Fusion to a Carrier Protein and a Synthetic Propeptide Enhances E7 HPV-16 Production and Secretion in Lactococcus lactis
  159. Intranasal Immunization with Recombinant Lactococcus lactis Secreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production
  160. Loss of Restriction Site DdeI, used for Avian Molecular Sexing, in Oreophasis derbianus
  161. Controlled Production of Stable Heterologous Proteins in Lactococcus lactis
  162. Molecular sexing of monomorphic endangeredArabirds
  163. Production of Human Papillomavirus Type 16 E7 Protein in Lactococcus lactis